title: The Targeted-liposome Delivery System of Antitumor Drugs.
abstract: The liposome delivery system has been intensively explored as novel drug delivery system (DDS) for antitumor drugs, due to its safety, selective cytotoxicity, long circulation and slow elimination in blood, which is favorable for cancer therapy. The liposome-based chemotherapeutics are used to treat a variety of cancers to enhance the therapeutic index of antitumor drugs. Here, the author reviewed the important targets for cancer therapy and the pharmacokinetic behavior of liposomal drugs in vivo, as well as the application of the targeting liposomal system in cancer therapy. Considering further application for clinical use, the great challenges of the liposome-based delivery system were also proposed as follows: 1) prepare stealth liposome with steric stabilization and further enhance the therapeutic effects and safety; 2) explore more safe clinical targets and complementary or different types of targeting liposome; 3) thirdly, more investment is needed on the research of pharmacokinetics of the elements such as the ligands (antibody), PEG and lipids of liposome delivery system as well as safety evaluation. Considering the complex process of the liposomal encapsulation drugs in vivo, the author inferred that there are maybe different forms of the encapsulation drug to be internalized by the tumor tissues at the same time and space, although there are little reports on it.
authors.forename: Wei-dang
authors.initials: WD
authors.lastname: Wu
authors.forename: Xiu-lin
authors.initials: XL
authors.lastname: Yi
authors.forename: Li-xin
authors.initials: LX
authors.lastname: Jiang
authors.forename: Ya-zhuo
authors.initials: YZ
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Gao
authors.forename: Yong
authors.initials: Y
authors.lastname: Zeng
authors.forename: Rong-da
authors.initials: RD
authors.lastname: Yi
authors.forename: Li-peng
authors.initials: LP
authors.lastname: Dai
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Ci
authors.forename: Duan-yun
authors.initials: DY
authors.lastname: Si
authors.affiliation: School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, People's Republic of China. liuchangxiao@vip.163.com.
authors.forename: Chang-xiao
authors.initials: CX
authors.lastname: Liu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D006801:Humans; D008024:Ligands; D008055:Lipids / Q000737:chemistry; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D008024:Ligands; D008055:Lipids; D008081:Liposomes; D011092:Polyethylene Glycols